Raphael Landovitz


Professor of Medicine in the Division of Infectious Diseases

UCLA Health

Dr. Raphael Landovitz is an infectious diseases doctor specializing in HIV/AIDS. Among other things, he led the HIV Prevention Trials Network research that found that a single injection every eight weeks of the drug cabotegravir protects against HIV infection for two months and is more effective for pre-exposure prophylaxis than the widely used daily oral drug Truvada. He is also a principal investigator in the UCLA arm of the AstraZeneca COVID-19 vaccine trial. He heads the Los Angeles County PEP Demonstration Project, collaborates with the City and County of Los Angeles, Friends Community Center, and works in the ACTG, HPTN and ATN clinical trials networks.

Return To Index

For reprint and licensing requests for this article, CLICK HERE.